Glatiramer Acetate 40 mg/mL in Relapsing–Remitting Multiple Sclerosis: A Review

@article{McKeage2015GlatiramerA4,
  title={Glatiramer Acetate 40 mg/mL in Relapsing–Remitting Multiple Sclerosis: A Review},
  author={K. McKeage},
  journal={CNS Drugs},
  year={2015},
  volume={29},
  pages={425-432}
}
Glatiramer acetate (Copaxone®) is a synthetic analogue of myelin basic protein, which is thought to be involved in the pathogenesis of multiple sclerosis (MS). The therapeutic effects of the drug in the treatment of MS are thought to be via immunomodulation and neuroprotection. Subcutaneous glatiramer acetate 20 mg/mL once daily is approved in several countries for the treatment of relapsing forms of MS. Recently, a high-concentration formulation of glatiramer acetate 40 mg/mL administered… Expand
[Efficacy, safety and tolerability of glatiramer acetate injections in dose 40 mg/ml in patients with relapsing-remitting multiple sclerosis].
TLDR
Glatiramer acetate GA in dose 40 mg/ml should be considered as a more convenient regimen for RRMS patients which can improve patients' adherence to treatment and as a result, its efficacy. Expand
Long-term safety and tolerability of glatiramer acetate 20 mg/ml in the treatment of relapsing forms of multiple sclerosis
TLDR
A database analysis of all patients with MS who have ever been exposed to GA 20 mg/mL daily in clinical trials, including patients with up to 20 years of continuous treatment, shows GA to be safe and generally well tolerated. Expand
A Review of Multiple Sclerosis Treatments: Interferon Beta, Glatiramer Acetate, Fingolimod, and Natalizumab
TLDR
The main focus of this review is to take an in depth look on four specific medications for treating MS: Interferon Beta, Glatiramer Acetate, Fingolimod, and Natalizumab. Expand
Atypical Post-Injection Reactions with Delayed Onset Following Glatiramer Acetate 40 mg: Need for Titration?
TLDR
Atypical PIRs with GA40, especially gastrointestinal symptoms and/or fever/shivering, had a delayed onset and occurred in a significant proportion of patients, and initial dose titration might reduce PIR frequency. Expand
Tolerability and Safety Profile of a New Brand-Generic Product of Glatiramer Acetate in Iranian Patients with Relapsing-Remitting Multiple Sclerosis: An Observational Cohort Study†
TLDR
The 40 mg brand-generic glatiramer acetate product was well tolerated in this selected group of Iranian patients with relapsing-remitting multiple sclerosis, and patient adherence was favorable over 1 year. Expand
Update on monitoring and adverse effects of first generation disease modifying therapies and their recently approved versions in relapsing forms of multiple sclerosis.
TLDR
Glatopa (a glatiramer acetate bioequivalent), now represents the first available generic alternative of a DMT for multiple sclerosis and its dosing, route of administration, and side effects are the same as for Copaxone. Expand
Differential Effects of MS Therapeutics on B Cells—Implications for Their Use and Failure in AQP4-Positive NMOSD Patients
TLDR
It is concluded that the differential effect of MS drugs on B cells is one potential parameter determining the therapeutic efficacy or failure in antibody-dependent diseases like seropositive NMOSD. Expand
Purified Cannabidiol, the main non-psychotropic component of Cannabis sativa, alone, counteracts neuronal apoptosis in experimental multiple sclerosis.
TLDR
It is demonstrated that, alone, purified CBD possesses an anti-apoptotic power against the neurodegenerative processes underlying MS development. Expand
The random co-polymer glatiramer acetate rapidly kills primary human leukocytes through sialic-acid-dependent cell membrane damage.
TLDR
It is reported that GA rapidly kills primary human T lymphocytes and, less actively, monocytes, and a consistent requirement of certain oligomeric and chemical properties to support cytotoxic effects of cationic polymers targeting human leukocytes. Expand
Long‐term, single‐arm, open‐label, multicenter phase 2/4 study of glatiramer acetate by subcutaneous injection in Japanese patients with relapsing–remitting multiple sclerosis
TLDR
The present open‐label study aimed to evaluate the efficacy and safety of long‐term treatment with GA in patients with multiple sclerosis with relapse. Expand
...
1
2
...

References

SHOWING 1-10 OF 43 REFERENCES
Glatiramer Acetate: A Review of Its Use in Patients with Relapsing-Remitting Multiple Sclerosis and in Delaying the Onset of Clinically Definite Multiple Sclerosis
TLDR
In clinical trials in patients with RRMS, glatiramer acetate reduced the frequency of relapses, was more effective than placebo and showed generally similar efficacy to subcutaneous interferon (IFN) β-1a and IFNβ-1b. Expand
The pharmacokinetics of glatiramer acetate for multiple sclerosis treatment
TLDR
The proven efficacy and the mild adverse events, makes GA a good therapeutic option in the early stage of the disease, and particularly useful for patients who suffer flu-like symptoms from other RRMS therapies as an alternative. Expand
Patient experience with glatiramer acetate 40 mg/1 mL three-times weekly treatment for relapsing-remitting multiple sclerosis: Results from the GLACIER extension study (P7.218)
TLDR
The extension phase of the GLACIER study demonstrates that patients converting from GA20 to GA40 perceive a convenience benefit and report fewer IRAEs. Expand
Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial
TLDR
There was no significant difference between interferon beta-1a and glatiramer acetate in the primary outcome, and the ability to predict clinical superiority on the basis of results from previous studies might be limited by a trial population with low disease activity. Expand
Efficacy and safety of a three-times-weekly dosing regimen of glatiramer acetate in relapsing–remitting multiple sclerosis patients: 3-year results of the Glatiramer Acetate Low-Frequency Administration open-label extension study
TLDR
GA40 conferred treatment benefit over 3 years: sustained low ARR and lesion activity and favorable safety and Adverse events were mild, consistent with the well-established glatiramer acetate (GA) safety profile. Expand
250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study
TLDR
Although interferon beta-1b and glatiramer acetate had different adverse event profiles, the overall tolerability to both drugs was similar and no differences in relapse risk, EDSS progression, T1-hypointense lesion volume, or normalised brain volume were found. Expand
Efficacy of treatment of MS with IFNβ-1b or glatiramer acetate by monthly brain MRI in the BECOME study
TLDR
Patients with relapsing multiple sclerosis randomized to interferon beta 1b or glatiramer acetate showed similar MRI and clinical activity as evidenced on frequent brain MRI. Expand
Efficacy and safety of a three-times weekly dosing regimen of glatiramer acetate in relapsing-remitting multiple sclerosis patients: 3-year results of the Glatiramer Acetate Low-frequency Administration (GALA) open-label extension study (P7.273)
TLDR
Early treatment with GA40 resulted in sustained reductions in ARR, lesion activity, and evolution of active lesions to chronic black holes over 36 months, consistent with the well-established GA safety profile. Expand
Advances in the treatment of relapsing - Remitting multiple sclerosis
TLDR
Patients′ clinical and paraclinical phenotypes and biomarker profile may help to elucidate disease subtypes and response to therapy in the future, thus allowing treatment individualization. Expand
Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial
TLDR
Early treatment with glatiramer acetate is efficacious in delaying conversion to clinically definite multiple sclerosis in patients presenting with clinically isolated syndrome and brain lesions detected by MRI. Expand
...
1
2
3
4
5
...